Form 4: Pediatrix Director Sells Over 10,000 Shares

Sentiment:

Insider Transaction Report 19 November 2025 5:00 PM

📋All filings for Pediatrix Medical Group, INC

Pediatrix Medical Group Director Michael A. Rucker sold 10,478 shares of common stock for $23.00 per share.

Worse than expectedA company director sold a substantial number of shares, which can be perceived negatively by investors as it might signal a lack of confidence or a belief that the stock is fully valued, despite being under a 10b5-1 plan.

Summary

Michael A. Rucker, a Director of Pediatrix Medical Group, Inc. (MD), sold 10,478 shares of common stock.
The transaction occurred on November 17, 2025.
The shares were sold at a weighted average price of $23.00 per share, with prices ranging from $23.00 to $23.02.
Following this transaction, Mr. Rucker beneficially owns 59,101 shares of Pediatrix Medical Group common stock.
The sale was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transaction.

Sentiment

Score: 3

Explanation: The sale of shares by a director, even under a pre-arranged 10b5-1 plan, typically signals a neutral to slightly negative sentiment from the insider regarding the stock's immediate upside potential.

Positives

The sale was executed under a Rule 10b5-1(c) plan, which suggests the transaction was pre-scheduled and not necessarily based on immediate, new material information.

Negatives

A Director, Michael A. Rucker, sold a significant number of shares (10,478) of company stock.
Insider selling can sometimes be interpreted by the market as a lack of confidence in the company's near-term prospects or that the stock is fully valued.

Future Outlook

Industry Context

This is an individual insider transaction within the healthcare services industry and does not directly reflect broader industry trends, though it occurs within the context of the company's operational environment.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Power of Attorney Grant	Michael A. Rucker granted a Power of Attorney to Mary Ann E. Moore and Tara McManus to handle SEC filings on his behalf, including Forms 3, 4, 5, Schedules 13D, 13G, and Forms 144.	10/28/2025	This streamlines the process for the director to comply with SEC reporting requirements, ensuring timely and accurate filings, and is a standard corporate governance practice for executives and directors.

Stakeholder Impact

Shareholders may interpret the director's sale as a signal about the company's future performance or stock valuation, potentially leading to negative sentiment or selling pressure on the stock.

Key Dates

Date	Description
10/28/2025	Date Power of Attorney was executed by Michael A. Rucker.
11/17/2025	Date of common stock transaction by Michael A. Rucker.
11/19/2025	Date Form 4 was signed by Attorney-in-Fact.

Recommendation

hold

While insider selling can be a negative signal, the transaction was executed under a Rule 10b5-1 plan, which suggests it was pre-scheduled and not necessarily based on new, adverse material information. Given this context, a 'Hold' recommendation is appropriate, advising investors to monitor future developments rather than making an immediate 'Sell' decision based solely on this filing.

Keywords

Pediatrix Medical Group, MD, Michael A. Rucker, insider trading, Form 4, stock sale, director, equity, beneficial ownership, 10b5-1 plan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.